Therefore, as seen in HER2-targeted agents, the novel CLDN18.2-targeting agents are also showing some potential results in tumours with low target expression, highlighting that the subgroup of patients that could benefit from these treatments could be wider [80]. Here, ERBB2 is linked to neoplasm.